Results 321 to 330 of about 204,414 (356)

Nuclear receptors and disease: androgen receptor [PDF]

Essays in Biochemistry, 2004
The androgen receptor (AR) protein regulates transcription of certain genes. Usually this depends upon a central DNA-binding domain that permits the binding of androgen–AR complexes to regulatory DNA sequences near or in a target gene. The AR also has a C-terminal ligand-binding domain and an Nterminal transcription modulatory domain.
Jianhui Wu, Mark Trifiro, Mark Trifiro, Lenore K. Beitel, Lenore K. Beitel, Youssef A. Elhaji, Youssef A. Elhaji, Bruce Gottlieb, Bruce Gottlieb   +8 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Androgen receptor polymorphism (CAG repeats) and androgenicity

Clinical Endocrinology, 2005
SummaryObjective  Polymorphism of the androgen receptor (AR) has been related to various pathophysiological conditions, such as osteoporosis and infertility. The objectives of this study were to evaluate the frequency of distribution in a normal Italian population and to assess CAG repeats (CAGr) in other conditions, such as hypoandrogenism ...
CANALE D, CAGLIERESI C, MOSCHINI C, LIBERATI CD, MACCHIA, ENRICO, PINCHERA, ALDO, MARTINO, ENIO   +6 more
openaire   +4 more sources

Androgen Receptor Dependence

2019
Androgens and the androgen receptor (AR) play crucial roles in the biology of normal and diseased prostate tissue, including prostate cancer (PCa). This dependence is evidenced by the use of androgen depletion therapy (ADT) as the primary treatment for locally advanced, metastatic, or relapsed PCa.
Aashi Chaturvedi, Scott M. Dehm
openaire   +3 more sources

[12] Trafficking of the androgen receptor

1999
Publisher Summary The androgen receptor (AR) belongs to the superfamily of nuclear receptors characterized by a common structure and mechanism of action. The AR is an androgen-dependent transcription factor composed of four domains: the amino-terminal transcription activation domain; the DNA-binding domain, which interacts with a specific DNA ...
Jean-Claude Nicolas, Béatrice Térouanne, Charles Sultan, Virginie Georget   +3 more
openaire   +3 more sources

Androgen Receptor and Estrogen Receptors

2002
The androgen receptor (AR) and the estrogen receptors (ER) are members of the nuclear receptor (NR) family. These NRs are distinguished from the other transcription factors by their ability to control gene expression upon ligand binding (steroids, retinoids, thyroid hormone, vitamin D, fatty acids, and other small hydrophobic molecules). Their combined
H. M. Oosterkamp, R. Bernards
openaire   +2 more sources

Androgens and androgen receptor in prostate and ovarian malignancies

Frontiers in Bioscience, 2003
The molecular and biochemical mechanisms contributing to the development and progression of both prostate and ovarian carcinogenesis are currently unknown. A better understanding of the cross-talk between endocrine, signal transduction and regulatory pathways in normal and neoplastic prostatic and ovarian tissues is necessary to elucidate malignant ...
Marianne D. Sadar, Katie Meehan
openaire   +3 more sources

Androgen dependency of the androgen receptor in rat epididymis

Biochemical and Biophysical Research Communications, 1975
Abstract Binding of radioactive androgen to the 8S epididymal receptor is reduced to undetectable levels after 30 days of castration. Testosterone propionate(200 μg/day)administered starting immediately after castration and continued for 30 days prevented the disappearance of binding activity.
Ricardo S. Calandra, Jorge A. Blaquier, Enrique Del Castillo, Marco A. Rivarola   +3 more
openaire   +3 more sources

The role of androgens and the androgen receptor in prostate cancer

Cancer Letters, 2002
Prostate cancer (PCa) is the leading diagnosed malignancy in men in western countries. The relationship between androgens and the androgen receptor (AR) has been studied extensively in PCa. Plasma levels of androgens show variations between different populations, and in many cases this correlates with PCa susceptibility.
Donald J. Tindall, Jose D. Debes
openaire   +3 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-vornhagen, Victoria Metaxa, Elie Azoulay   +2 more
exaly